Skip to content
  • About Us
  • Privacy Policy
  • Contact Us
B2B Newz

B2B Newz

Daily Industry News & Updates

  • Top Stories
  • Business
  • Technology
  • Health
  • Science
  • Toggle search form
FDA Uncertainty Takes Its Toll On Bioshares

FDA Uncertainty Takes Its Toll On Bioshares

Posted on March 18, 2019 By Nicholas Miller

The surprising announcement by Commissioner of Food and Drug Administration of US that he will be stepping down from his role next month has created chaos in the biotech sector forcing the industry to face its worst ever decline in share markets. Biotech analysts say that this was due to shock in the industry about how his exit will affect small innovation driven biotech firms. The Nasdaq Biotech Index which is traded heavily fell by 5% within three days of the announcement by FDA commissioner Scott Gottlieb. The NYSE Arca Biotech Index for large caps fell by 4% during the same period.

Analysts say that biotech investors are concerned that without the expert leadership of Gottlieb the agency is likely to lose its momentum on the efforts being made to pressurize pharma companies to open up their processes for creation of biosimilar drugs that are in reality the generic equivalent of novel drugs. Under the leadership of Gottlieb FDA had managed to get around 59 drugs approved in one year along with obtaining clearances for introduction of 971 generic drugs including launch of generic versions of critical medical tools like EpiPen and asthma treatment inhaler Advair.

Though there is hope that introduction of drugs in the line of gene therapy and cell therapy may get approved with the same speed as now but generic approvals for drugs might slow down. The fast pace of drug approval under the outgoing commissioner had also been a cause for concern as it was leading to underperformance in generic drug sector and significant erosion in prices and margins as per a recent research note submitted by S&P analysts. According to experts two generic drug making companies namely Teva pharmaceuticals and Mylan could benefit from the slowdown in generic drug approvals after the departure of FDA commissioner.

Top Stories

Post navigation

Previous Post: Popular Paris Street Want To Shun Instagrammers
Next Post: Medication Made Affordable Through Employer-Sponsored Plans By UnitedHealth

Related Posts

San Francisco Plan Might Ban Government Employment Of Facial Recognition San Francisco Plan Might Ban Government Employment Of Facial Recognition Technology
UK Registers Slowest Growth After 2012 UK Registers Slowest Growth After 2012 Top Stories
Study Reveals The Possibility Of Destroying Cancer Cells With Metal Iridium Study Reveals The Possibility Of Destroying Cancer Cells With Metal Iridium Top Stories
Superman-like Artificial Skin Could Give The Burnt Victims A Chance To Feel Superman-like Artificial Skin Could Give The Burnt Victims A Chance To Feel Health
Young Adults And Teens Are More Depressed As Compare To The Mid Of 2000s Young Adults And Teens Are More Depressed As Compare To The Mid Of 2000s Top Stories
WhatsApp Can Now Be Locked With Touch ID Or Face ID WhatsApp Can Now Be Locked With Touch ID Or Face ID Top Stories

Follow us

follow us

Recent Posts

  • Global Tissue Diagnostics Market Business Revenue by Top Leading Players and their Strategies to grow up 2022
  • Global Hybrid Operating Room Market Latest trends & dynamics, Market opportunities and Forecast 2022-2028
  • Global Magnetic Resonance Imaging Systems Market Industry Growth Factor, Overview, Demand, and Current Trends with Forecast to 2028
  • Global Microfluidic Components Market Industrial Report to Cover Process Analysis, Manufacturing Cost Structure 2022-2028
  • Global Healthcare Decision Support System Market Latest trends & dynamics, Market opportunities and Forecast 2022-2028

Who We Are

Every day, people staying around, are looking for information to better understand their journey towards future. Recognizing the challenge of finding a trusted local source of news and information, B2B News is a trusted destination for news impacting with the precise fusion of trust, reliability, genuine information crafted in the inspiring stories and many other forms of information.

Get In Touch With us

B2B News Update
2717 Wilmarco Ave,
Baltimore, MD 21223, USA
Phone: +1 410-941-6063
Email: contact@b2bnewz.com

b2bnewsUpdate_logo

Copyright © 2023 B2B Newz.

Powered by PressBook Media WordPress theme